News | November 01, 2024
AstraZeneca China President currently under investigation
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
The patient has been isolated in a designated hospital and is currently stable
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
